摘要
目的:探讨HCC患者经肝动脉灌注化疗栓塞术(TACE)治疗前、后p16基因甲基化、AFP和sVEGF变化的临床意义。方法:采用甲基化特异性PCR(MSP)法检测56例HCC患者血清p16基因甲基化率,ELISA法检测AFP和sVEGF。结果:HCC患者血清p16基因甲基化检出率为69.6%(39/56),AFP阳性检出率为80.4%(45/56),sVEGF阳性检出率为73.2%(41/56)。结论:血清DNA中p16基因甲基化检测可作为HCC分子诊断标志,三者联合检测对肝癌诊断有实用价值。
Objective：To investigate the clinical significance of p16 gene methylation status with AFP and serum VEGF before and after hepatic artery chemoembolization（TACE） treatment of HCC patients.Methods：To use methylation specific PCR（MSP） to determine serum p16 gene methylation rate,ELISA detection for AFP and serum VEGF in 56 patients with HCC.Results：Serum p16 gene methylation detection rate was 69.6%（39/56）,AFP positive detection rate was 80.4%（45/56）,serum VEGF positive rate was 73.2%（41/56） in 56 patients with HCC.Conclusion：p16 gene methylation detection in the serum DNA can be used as diagnostic marker of HCC molecule,it has practical value in the combined detection for HCC diagnosis.
出处
《现代肿瘤医学》
CAS
2013年第6期1277-1279,共3页
Journal of Modern Oncology
基金
陕西省教育厅科技基金(编号:11JK0709)
延安大学附属医院研究生创新基金(编号:10YJ59)
